Related Experiment Video
Updated: Dec 29, 2025
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
In vitro benchmarking of NF-κB inhibitors
Alexandria P Harrold1, Megan M Cleary1, Narendra Bharathy1
1Children's Cancer Therapy Development Institute, Beaverton, OR, 97005, USA.
Abstract:
Dysregulated activity of the transcription factors of the nuclear factor κb (NF-κB) family has been implicated in numerous cancer types, inflammatory diseases, autoimmune disease, and other disorders. As such, selective NF-κB pathway inhibition is an attractive target to researchers for preclinical and clinical drug development. A plethora of commercially and clinically available inhibitors claim to be NF-κB specific; however, such claims of specificity are rarely quantitative or benchmarked, making the biomedical literature difficult to contextualize. This imprecision is worsened because some NF-κB reporter systems have low signal-to-noise ratios. Herein, we use a robust, defined, commercially available reporter system to benchmark NF-κB agonists and antagonists for the field. We also functionally characterize a RELA fusion-positive ependymoma cell culture with validated NF-κB inhibitor compounds.
Insights
Researchers benchmarked nuclear factor kappa B (NF-κB) pathway inhibitors using a reliable reporter system. This study provides crucial data for developing targeted NF-κB therapies for various diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Nuclear factor kappa B (NF-κB) pathway dysregulation is linked to cancer, inflammation, and autoimmune disorders.
- Targeting the NF-κB pathway is a key strategy in drug development for these diseases.
- Existing NF-κB inhibitors lack quantitative specificity data, complicating research interpretation.
Purpose of the Study:
- To quantitatively benchmark NF-κB agonists and antagonists using a robust reporter system.
- To provide a reliable tool for the scientific community to contextualize NF-κB research.
- To functionally characterize a RELA fusion-positive ependymoma cell line with validated inhibitors.
Main Methods:
- Utilized a defined, commercially available reporter system for high signal-to-noise ratio measurements.
- Benchmarked a range of NF-κB pathway agonists and antagonists.
- Performed functional characterization of ependymoma cells treated with NF-κB inhibitors.
Main Results:
- Established a quantitative benchmark for NF-κB inhibitor specificity.
- Demonstrated the utility of the reporter system for evaluating pathway modulators.
- Provided functional data on NF-κB inhibition in a relevant cancer model.
Conclusions:
- The developed benchmarking system enhances the reliability of NF-κB research.
- Accurate characterization of NF-κB inhibitors is essential for effective drug development.
- This work facilitates the precise targeting of the NF-κB pathway in disease treatment.
More Related Videos
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
